Literature DB >> 16966829

Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy.

Hiroki Fujita1, Tsukasa Morii, Jun Koshimura, Motoko Ishikawa, Masako Kato, Takeshi Miura, Hiroshi Sasaki, Takuma Narita, Seiki Ito, Masafumi Kakei.   

Abstract

Adiponectin is an adipose-derived protein which has anti-inflammatory and anti-atherogenic properties in addition to insulin-sensitizing effects. To date, the role of adiponectin in the pathogenesis of diabetic nephropathy remains unclear. The aim of the present study was to explore the relationship between adiponectin and renal tubular injury in diabetic nephropathy. We determined serum and urinary adiponectin levels in type 2 diabetic patients with normoalbuminuria (n = 19), microalbuminuria (n = 18), and overt diabetic nephropathy (n = 16), and then analyzed the correlations between serum and urinary adiponectin, urinary N-acetylglucosaminidase (NAG) as a clinical marker of renal tubular injury, urinary monocyte chemoattractant protein-1 (MCP-1) as an inflammatory marker in renal tubulointerstitium, and clinical markers of renal disease. Notably, serum and urinary adiponectin levels were significantly increased in patients with overt diabetic nephropathy compared to those with normoalbuminuria and microalbuminuria. In univariate linear regression analysis, serum adiponectin levels were positively correlated with serum creatinine (r = 0.648, P<0.0001), urinary albumin (r = 0.583, P<0.0001), urinary NAG (r = 0.406, P<0.01), urinary MCP-1 (r = 0.514, P<0.0001), and urinary adiponectin (r = 0.691, P<0.0001) levels in all diabetic patients. Urinary adiponectin levels were also positively correlated with serum creatinine (r = 0.729, P<0.0001), urinary albumin (r = 0.799, P<0.0001), urinary NAG (r = 0.701, P<0.0001), and urinary MCP-1 (r = 0.801, P<0.0001) levels in all diabetic patients. Multiple linear regression analysis showed that serum creatinine and urinary adiponectin levels were independently associated with serum adiponectin levels (r(2) = 0.522), and that serum creatinine, urinary NAG, urinary MCP-1, and serum adiponectin levels were independent determinants of urinary adiponectin levels (r(2) = 0.851). These results collectively indicate that renal insufficiency and tubular injury possibly play a contributory role in increases in serum and urinary adiponectin levels in overt diabetic nephropathy. We presume that an increase in circulating adiponectin in overt diabetic nephropathy might be a physiological response to mitigate renal tubular injury and to prevent the further progression of diabetic nephropathy through its anti-inflammatory and anti-atherogenic effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966829     DOI: 10.1507/endocrj.k06-016

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  16 in total

1.  Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

Authors:  Boris Guiu; Elodie Crevisy-Girod; Christine Binquet; Laurence Duvillard; David Masson; Côme Lepage; Samia Hamza; Denis Krausé; Bruno Verges; Anne Minello; Jean-Pierre Cercueil; Patrick Hillon; Jean-Michel Petit
Journal:  Eur Radiol       Date:  2011-11-20       Impact factor: 5.315

2.  Relationship between serum cystatin C and serum adiponectin level in type 2 diabetic patients.

Authors:  Yoshiya Hosokawa; Yuya Yamada; Yoshinari Obata; Megu Yamaguchi Baden; Kenji Saisho; Arisa Ihara; Koji Yamamoto; Kiyonori Katsuragi; Yuji Matsuzawa
Journal:  Clin Exp Nephrol       Date:  2011-11-30       Impact factor: 2.801

3.  Adiponectin in children and young adults with focal segmental glomerulosclerosis.

Authors:  Christine B Sethna; Valerie Boone; Jonas Kwok; Daniel Jun; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2015-06-27       Impact factor: 3.714

4.  Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.

Authors:  Susumu Ogawa; Takefumi Mori; Kazuhiro Nako; Tsuneo Ishizuka; Sadayoshi Ito
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

Review 5.  The Promise of Systems Biology for Diabetic Kidney Disease.

Authors:  Frank C Brosius; Wenjun Ju
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

6.  Association of serum adiponectin level with albuminuria in chronic kidney disease patients.

Authors:  Ha Yeon Kim; Eun Hui Bae; Seong Kwon Ma; Dong Wan Chae; Kyu Hun Choi; Yong-Soo Kim; Young-Hwan Hwang; Curie Ahn; Soo Wan Kim
Journal:  Clin Exp Nephrol       Date:  2015-10-07       Impact factor: 2.801

Review 7.  The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.

Authors:  Tomás P Griffin; William Patrick Martin; Nahidul Islam; Timothy O'Brien; Matthew D Griffin
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

8.  Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy.

Authors:  Anna Tavridou; Anastasia Georgoulidou; Athanasios Roumeliotis; Stefanos Roumeliotis; Efstathia Giannakopoulou; Nikolaos Papanas; Ploumis Passadakis; Vangelis G Manolopoulos; Vassilis Vargemezis
Journal:  J Diabetes Res       Date:  2015-05-12       Impact factor: 4.011

9.  Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort.

Authors:  Kieren J Mather; Qing Pan; William C Knowler; Tohru Funahashi; George A Bray; Richard Arakaki; Bonita Falkner; Kumar Sharma; Barry J Goldstein
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

10.  Serum levels of adiponectin and leptin as biomarkers of proteinuria in lupus nephritis.

Authors:  Valeria Diaz-Rizo; David Bonilla-Lara; Laura Gonzalez-Lopez; Dalia Sanchez-Mosco; Nicte S Fajardo-Robledo; Edsaul E Perez-Guerrero; N Alejandra Rodriguez-Jimenez; A Miriam Saldaña-Cruz; M Luisa Vazquez-Villegas; Eduardo Gomez-Bañuelos; Monica Vazquez-Del Mercado; E German Cardona-Muñoz; David Cardona-Muller; Xochitl Trujillo; Miguel Huerta; Mario Salazar-Paramo; Jorge I Gamez-Nava
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.